Photo by gervele from unsplash
In this short perspective, the chemical structure, physical properties, synthesis, mechanism of action, and pharmacokinetic profile of pacritinib are summarized. It is an orally bioavailable and isoform-selective JAK-2 inhibitor for… Click to show full abstract
In this short perspective, the chemical structure, physical properties, synthesis, mechanism of action, and pharmacokinetic profile of pacritinib are summarized. It is an orally bioavailable and isoform-selective JAK-2 inhibitor for treating patients with myelofibrosis.
Keywords:
inhibitor;
pacritinib selective;
pacritinib;
first approval;
approval pacritinib;
patients myelofibrosis
Journal Title: Anti-cancer agents in medicinal chemistry
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Anti-cancer agents in medicinal chemistry
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!